The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on menopausal hormone therapy for the primary prevention of chronic conditions. Based on its review of the evidence, the Task Force recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. This is a D recommendation. The Task Force also recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had their uterus removed. This is a D recommendation. The draft recommendation statement and draft evidence review are available for review and public comment from May 16, 2017 to June 12, 2017 at /uspstf/public-comments-and-nominations/opportunity-for-public-comment.
